A resurging boom in new drugs for epilepsy and brain disorders. (Q48093388)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28956955%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

title

A resurging boom in new drugs for epilepsy and brain disorders (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28956955%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28956955%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

Iyan Younus

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28956955%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

language of work or name

English

0 references

publication date

23 October 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28956955%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Clinical Pharmacology

31 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28956955%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28956955%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28956955%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

page(s)

27-45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28956955%20AND%20SRC:MED&resulttype=core&format=json

The descriptive epidemiology of epilepsy-a review

31 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Epigenetic interventions for epileptogenesis: A new frontier for curing epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Neurosteroids: endogenous role in the human brain and therapeutic potentials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Neuroactive steroids for the treatment of status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Pharmacokinetic and behavioral effects of allopregnanolone in healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Acute and chronic effects of the synthetic neuroactive steroid, ganaxolone, against the convulsive and lethal effects of pentylenetetrazol in seizure-kindled mice: comparison with diazepam and valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Neurosteroids for the potential protection of humans against organophosphate toxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Antiseizure Activity of Midazolam in Mice Lacking δ-Subunit Extrasynaptic GABA(A) Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

The 2011 E. B. Hershberg award for important discoveries in medicinally active substances: (1S,3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115), a GABA aminotransferase inactivator and new treatment for drug addiction and infantile s

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

A case report on the efficacy of vigabatrin analogue (1S, 3S)-3-amino-4-difluoromethylenyl-1-cyclopentanoic acid (CPP-115) in a patient with infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Mechanism of inactivation of γ-aminobutyric acid aminotransferase by (1S,3S)-3-amino-4-difluoromethylene-1-cyclopentanoic acid (CPP-115)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

The Pharmacological Basis of Cannabis Therapy for Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

The Utility of Cannabidiol in the Treatment of Refractory Epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Cannabinoids in treatment-resistant epilepsy: A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Cannabidiol as potential treatment in refractory pediatric epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Molecular Targets of Cannabidiol in Neurological Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Epilepsy: Cannabidiol reduces seizure frequency in Dravet syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Cannabidivarin is anticonvulsant in mouse and rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a CB1 receptor-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Cation-chloride cotransporters in neuronal development, plasticity and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

The bumetanide prodrug BUM5, but not bumetanide, potentiates the antiseizure effect of phenobarbital in adult epileptic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Blocking seizures with the diuretic bumetanide: promises and pitfalls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Erratum to: A Mechanism to Explain Ototoxicity in Neonates Exposed to Bumetanide: Lessons to Help Improve Future Product Development in Neonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Failure of the Nemo Trial: Bumetanide Is a Promising Agent to Treat Many Brain Disorders but Not Newborn Seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

The search for NKCC1-selective drugs for the treatment of epilepsy: Structure-function relationship of bumetanide and various bumetanide derivatives in inhibiting the human cation-chloride cotransporter NKCC1A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

mTOR inhibitors as a new therapeutic option for epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Pentylenetetrazole-induced seizures cause acute, but not chronic, mTOR pathway activation in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

mTOR inhibition modulates epileptogenesis, seizures and depressive behavior in a genetic rat model of absence epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Single-channel activity of the Ca2+-dependent K+ channel is modulated by FK506 and rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Activity- and mTOR-dependent suppression of Kv1.1 channel mRNA translation in dendrites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

A role for the mTOR pathway in surface expression of AMPA receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Clinical pharmacokinetics of everolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

A New SV2A Ligand for Epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

In vivo profile of ICA-27243 [N-(6-chloro-pyridin-3-yl)-3,4-difluoro-benzamide], a potent and selective KCNQ2/Q3 (Kv7.2/Kv7.3) activator in rodent anticonvulsant models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Upregulation of adenosine kinase in astrocytes in experimental and human temporal lobe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

The Biochemistry and Epigenetics of Epilepsy: Focus on Adenosine and Glycine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Anticonvulsant and antiepileptic actions of 2-deoxy-D-glucose in epilepsy models

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Anticonvulsant and proconvulsant actions of 2-deoxy-D-glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

2-Deoxy-d-glucose enhances tonic inhibition through the neurosteroid-mediated activation of extrasynaptic GABAA receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Chronic ingestion of 2-deoxy-D-glucose induces cardiac vacuolization and increases mortality in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Behavioral, cognitive, and safety profile of 2-deoxy-2-glucose (2DG) in adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Valnoctamide enhances phasic inhibition: a potential target mechanism for the treatment of benzodiazepine-refractory status epilepticus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

The potential of sec-butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

sec-Butyl-propylacetamide (SPD) and two of its stereoisomers rapidly terminate paraoxon-induced status epilepticus in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Pharmacokinetic-Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Engineering galanin analogues that discriminate between GalR1 and GalR2 receptor subtypes and exhibit anticonvulsant activity following systemic delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Galanin type 2 receptors regulate neuronal survival, susceptibility to seizures and seizure-induced neurogenesis in the dentate gyrus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Regulation of limbic status epilepticus by hippocampal galanin type 1 and type 2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Preclinical evaluation of intravenous NAX 810-2, a novel GalR2-preferring analog, for anticonvulsant efficacy and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Huperzine A prophylaxis against pentylenetetrazole-induced seizures in rats is associated with increased cortical inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Pharmacokinetics of fenfluramine enantiomers in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Valvular heart disease associated with fenfluramine-phentermine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Minocycline- and tetracycline-class antibiotics are protective against partial seizures in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Minocycline attenuates microglia activation and blocks the long-term epileptogenic effects of early-life seizures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Minocycline exerts acute inhibitory effects on cerebral cortex excitability in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Effects of PRX-00023, a novel, selective serotonin 1A receptor agonist on measures of anxiety and depression in generalized anxiety disorder: results of a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Epilepsy and serotonin (5HT): variations of 5HT-related genes in temporal lobe epilepsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

21 January 2018

Serotonin and epilepsy

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Tolerability, pharmacokinetics, and neuroendocrine effects of PRX-00023, a novel 5-HT1A agonist, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Interleukin-1β biosynthesis inhibition reduces acute seizures and drug resistant chronic epileptic activity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

The role of inflammation in epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

The role of inflammation in epileptogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Interleukin Converting Enzyme inhibition impairs kindling epileptogenesis in rats by blocking astrocytic IL-1beta production

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

New avenues for anti-epileptic drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Wide-field in vivo neocortical calcium dye imaging using a convection-enhanced loading technique combined with simultaneous multiwavelength imaging of voltage-sensitive dyes and hemodynamic signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Optogenetic tools for modulating and probing the epileptic network

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

Progress in Epilepsy: Latest Waves of Discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17512433.2018.1386553

10.1080/17512433.2018.1386553

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28956955%20AND%20SRC:MED&resulttype=core&format=json

31 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28956955%20AND%20SRC:MED&resulttype=core&format=json